Study guide

2.4 Cellular Phases of Burn Wound Healing and Scar Pathobiology

Certified Burn Registered Nurse CBRN

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Foundations of Burn Care

1.1 CBRN Exam Format, Eligibility, and BCEN Testing Standards 1.2 Anatomy, Histology, and Barrier Functions of the Skin 1.3 Burn Depth Classification and Jackson's Thermal Wound Zones

2 Chapter 2: Pathophysiology of Burn Injury & Systemic Response

2.1 Cellular Pathophysiology and Capillary Permeability in Burn Shock 2.2 Systemic Inflammatory Response Syndrome (SIRS) and MODS 2.3 Pathophysiology of Supraglottic, Subglottic, and Inhalational Injury 2.4 Cellular Phases of Burn Wound Healing and Scar Pathobiology

3 Chapter 3: Prehospital Triage, Primary Survey & Transfer Criteria

3.1 Initial Assessment, Primary Survey (ABCDEF), and Field Stabilization 3.2 Total Body Surface Area (TBSA) Calculation: Rule of Nines, Lund-Browder, and Palmar Method 3.3 American Burn Association (ABA) Burn Center Referral Criteria and Transport Logistics

4 Chapter 4: Fluid Resuscitation & Hemodynamic Stabilization (<72 Hours)

4.1 Fluid Resuscitation Formulas: Parkland (Baxter), Modified Brooke, and Consensus Protocols 4.2 Resuscitation Endpoints: Urine Output Titration, Base Deficit, and Hemodynamic Monitoring 4.3 Complications of Fluid Creep and Intra-Abdominal Hypertension / Abdominal Compartment Syndrome 4.4 Extremity Compartment Syndrome, Monitoring, and Emergent Escharotomy / Fasciotomy

5 Chapter 5: Airway Management & Inhalation Injury Management

5.1 Upper Airway Compromise, Indications for Early Endotracheal Intubation, and Airway Stabilization 5.2 Lower Airway Chemical Tracheobronchitis, Diagnostic Bronchoscopy, and Lung-Protective Mechanical Ventilation 5.3 Carbon Monoxide (CO) Toxicity, Cyanide Poisoning, and Specific Antidotes (Hydroxocobalamin)

6 Chapter 6: Acute Multisystem Assessment & Critical Care Management

6.1 Cardiovascular Derangements, Myocardial Depression, and Hemodynamic Optimization 6.2 Acute Kidney Injury, Rhabdomyolysis / Myoglobinuria, and Fluid-Electrolyte Shifts 6.3 Gastrointestinal Complications, Ileus, Early Enteral Nutrition, and Curling's Ulcer Prophylaxis 6.4 Neurological Impairment, Anemia of Burn Injury, Coagulopathy, and Musculoskeletal Protection

7 Chapter 7: Hypermetabolism & Nutritional Support

7.1 The Biphasic Metabolic Response: Ebb vs. Flow Phases and Persistent Hypermetabolism 7.2 Indirect Calorimetry, Caloric Equations (Curreri/Toronto), and Micronutrient / Trace Mineral Needs 7.3 Pharmacological Modulation: Propranolol, Oxandrolone, Growth Hormone, and Exercise Therapy 7.4 Stress Hyperglycemia, Intensive Insulin Protocols, and Adrenal / Thyroid Axis Dysregulation

8 Chapter 8: Pain Management in Burn Care

8.1 Pain Classification in Burns: Background, Procedural, Breakthrough, and Chronic Neuropathic Pain 8.2 Multimodal Analgesia: Opioids, Ketamine, Gabapentinoids, NSAIDs, and Regional Anesthesia 8.3 Non-Pharmacological Modalities: Virtual Reality, Cognitive Behavioral Techniques, Hypnosis, and Distraction

9 Chapter 9: Agitation, Delirium & Post-Burn Pruritus

9.1 Agitation Management, Targeted Sedation Protocols (RASS/SAS), and Circadian Rhythm Support 9.2 ICU Delirium: Risk Factors, Screening (CAM-ICU/ICDSC), Non-Pharmacological Bundles, and Medical Management 9.3 Post-Burn Itch: Histaminergic vs. Neuropathic Pruritus, Oral Antihistamines, Gabapentin, and Topical Emollients

10 Chapter 10: Burn Wound Assessment, Topical Antimicrobials & Dressings

10.1 Serial Wound Bed Assessment, Tissue Perfusion, and Documentation Standards 10.2 Topical Antimicrobial Formulations: Silver Sulfadiazine, Mafenide Acetate, Silver Nitrate, and Modern Silver Dressings 10.3 Wound Bed Preparation: Surgical, Enzymatic (Collagenase/Bromelain), Autolytic, and Mechanical Debridement 10.4 Modern Dressings, Hydrogels, Foam Dressings, Negative Pressure Wound Therapy (NPWT), and Moisture Retentive Balances

11 Chapter 11: Surgical Excision, Skin Grafting & Wound Closure

11.1 Principles of Early Tangential vs. Fascial Surgical Excision and Blood Conservation 11.2 Split-Thickness and Full-Thickness Autografting: Mesh Expansion Ratios vs. Sheet Grafts 11.3 Biologic Coverings, Dermal Regeneration Templates (Integra/Novosorb BTM), Allograft, and Xenograft 11.4 Autologous Cell Suspensions (ReCell), Cultured Epithelial Autografts (CEA), and Donor Site Management

12 Chapter 12: Burn Sepsis, Infection Control & Antimicrobial Therapy

12.1 Burn Center Infection Control: Contact Precautions, Hydrotherapy Sanitation, and Environmental Controls 12.2 Differentiating Hypermetabolic SIRS from Burn Sepsis: ABA Consensus Sepsis Criteria 12.3 Common Burn Pathogens (Pseudomonas, MRSA, Acinetobacter, Candida, Aspergillus) and Empiric Coverage 12.4 Invasive Burn Wound Infection: Clinical Signs, Quantitative Biopsy (>10^5 CFU/g), and Histopathological Invasion

13 Chapter 13: Specific Burn Etiologies: Electrical, Chemical & Cold Injuries

13.1 Electrical Burn Injuries: High-Voltage vs. Low-Voltage, Arc/Flash, Cardiac Monitoring, and Deep Muscle Necrosis 13.2 Chemical Injuries: Acids (Coagulation Necrosis), Alkalis (Liquefactive Necrosis), Hydrofluoric Acid (Calcium Gluconate), and Decontamination 13.3 Radiation Burns, Cutaneous Radiation Syndrome, Cold Injuries (Frostbite Triage and Thawing Protocols), and Vasodilator Therapy

14 Chapter 14: Special Burn Populations & Cutaneous Syndromes

14.1 Pediatric Burn Resuscitation (Maintenance Fluids + D5W), Surface Area Dynamics, and Non-Accidental Trauma Screening 14.2 Geriatric Burn Care: Thin Dermis, Altered Fluid Tolerance, Pre-existing Comorbidities, and Mortality Prognostication (Baux Score) 14.3 Burn Injury in Pregnancy: Maternal Physiology, Resuscitation, and Fetal Surveillance 14.4 Severe Cutaneous Adverse Reactions: Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), SCORTEN, and Specialized Burn Unit Nursing 14.5 Necrotizing Soft Tissue Infections and Friction/Shear Injuries

15 Chapter 15: Rehabilitation, Scar Management & Reconstruction

15.1 Anti-Deformity Positioning, Range-of-Motion Exercises, and Custom Splinting Across Major Joints 15.2 Hypertrophic Scarring Mechanisms, Myofibroblasts, and Vancouver Scar Scale (VSS) Assessment 15.3 Custom Pressure Garments (20-30 mmHg), Silicone Sheeting, Fractional CO2 Laser Resurfacing, and Contracture Release 15.4 Psychosocial Recovery, Post-Traumatic Stress Disorder (PTSD), Body Image Adaptation, Peer Support (Phoenix Society), and School/Work Reintegration 15.5 Discharge Teaching, Transition to Ambulatory Care, and Home Management

16 Chapter 16: Professional Practice, Ethics, Quality & Disaster Triage

16.1 Ethical Dilemmas in Burn Critical Care, Surrogate Decision-Making, Futility, and Palliative / End-of-Life Symptom Management 16.2 Interprofessional Burn Team Roles, Multidisciplinary Rounds, Structured Handoffs, and Patient/Family Advocacy 16.3 Burn Quality Improvement, American Burn Association (ABA) Verification Standards, and National Burn Repository (NBR) Benchmarking 16.4 Diversity, Equity, Inclusion, and Intraprofessional Nursing Development 16.5 Community Outreach, Burn Prevention Education, and Home Safety 16.6 Mass Casualty Burn Disasters, Secondary Triage Schemes (ABA/ABLS Triage Matrix), Surge Capacity, and CBRN/HAZMAT Emergency Response

2.4 Cellular Phases of Burn Wound Healing and Scar Pathobiology

Key Takeaways Explain This Topic AI

Burn wound healing progresses through four highly regulated, overlapping cellular phases: hemostasis (minutes), inflammation (days 1-4), proliferation (days 4-21), and remodeling/maturation (day 21 to 1-2 years).

The proliferative phase features fibroblast migration, provisional Type III collagen deposition, angiogenesis driven by VEGF, and re-epithelialization from wound margins and preserved dermal adnexa.

During the remodeling phase, provisional Type III collagen is systematically degraded and replaced by dense, organized Type I collagen bundles along lines of mechanical tension.

Under the '21-Day Rule', burn wounds that require longer than 21 days to achieve spontaneous closure exhibit an exponentially higher risk (>70-80%) of hypertrophic scarring.

Hypertrophic scars remain confined within the original wound boundaries and feature high myofibroblast density driven by excessive TGF-β1/2, whereas keloids invade surrounding uninjured tissue.

Last updated: August 2026

2.4 Cellular Phases of Burn Wound Healing and Scar Pathobiology

Core Principle: Cutaneous burn wound healing is an intricate, dynamic biological process designed to restore the barrier integrity of the skin. Unlike clean incisional surgical wounds, thermal burn wounds involve a massive zone of non-viable coagulated protein (eschar), persistent ischemia, and prolonged inflammatory signaling. Understanding the cellular transitions between hemostasis, inflammation, proliferation, and remodeling is vital to predicting pathological fibrogenesis, hypertrophic scar formation, and the necessity for early surgical excision.

  • 1. The Four Overlapping Cellular Phases of Wound Healing Relative Cellular
  • Activity / Biomass
  • ▲
  • │ ┌──────────────┐
  • │ │ 1. Hemostasis│ ┌────────────────┐
  • │ └──────┬───────┘ │ 2. Inflammation│ ┌─────────────────┐
  • │ │ └───────┬────────┘ │ 3. Proliferation │ ┌──────────────────┐
  • MAX │ │ │ └────────┬────────┘ │ 4. Remodeling & │
  • │ ▼ ▼ ▼ │ Maturation │
  • │ Platelets Neutrophils Fibroblasts └────────┬──────────┘
  • │ Fibrin Macrophages Angiogenesis ▼
  • │ PDGF Phagocytosis Type III Collagen Type I Collagen
  • │ M1 -> M2 Shift Epithelialization Myofibroblasts (α-SMA)
  • MIN │ Tensile Strength -> 80%
  • └───┴───────────────┴─────────────────┴───────────────────┴───────────────────────►
  • 0 hrs Day 1-4 Day 4-21 Day 21 to 1-2 Years
  • Phase 1: Hemostasis (Minutes to Hours Post-Injury)

Vascular Event : Immediate transient microvascular vasoconstriction (mediated by endothelin-1, thromboxane A2, and sympathetic discharge) lasting 5–10 minutes to limit immediate hemorrhage.

Cellular & Molecular Cascade : Platelets adhere to exposed subendothelial collagen via von Willebrand factor (vWF) and glycoprotein Ib/IIb/IIIa receptors. Platelet degranulation releases:

Platelet-Derived Growth Factor (PDGF) : Potent chemoattractant for neutrophils and fibroblasts.

Transforming Growth Factor-beta (TGF-β) : Initiates the fibrogenic and inflammatory signaling cascades.

Epidermal Growth Factor (EGF) : Stimulates subsequent keratinocyte proliferation.

Provisional Matrix : Thrombin cleaves fibrinogen into fibrin, creating a three-dimensional fibrin-fibronectin scaffold that anchors infiltrating inflammatory cells.

Phase 2: Inflammatory Phase (Days 1 to 4)

Neutrophil Influx (First 24–48 Hours) : Driven by IL-8, leukotriene B4 (LTB4), and complement fragment C5a. Neutrophils phagocytose bacteria, necrotic debris, and denatured protein. They release reactive oxygen species (ROS) and matrix metalloproteinases ( MMPs , such as MMP-8/neutrophil collagenase).

Macrophage Transition (Days 2 to 5) : Monocytes marginate and differentiate into tissue macrophages. Macrophages serve as the essential orchestrators of wound repair:

M1 Macrophages (Pro-inflammatory) : Clear cellular debris and sustain antimicrobial defenses.

M2 Macrophages (Pro-reparative) : Secrete growth factors that drive the transition into the proliferative phase: Vascular Endothelial Growth Factor ( VEGF ), basic Fibroblast Growth Factor ( bFGF ), and TGF-β1 .

Phase 3: Proliferative Phase (Days 4 to 21)

Fibroplasia & Provisional Matrix : Dermal fibroblasts migrate along the fibrin scaffold, proliferate, and synthesize abundant extracellular matrix (ECM) rich in Type III collagen , hyaluronic acid, and proteoglycans.

Angiogenesis (Granulation Tissue) : Endothelial cells respond to VEGF and bFGF by forming capillary buds (neovascularization), creating beefy-red, highly vascular, and fragile granulation tissue .

Re-epithelialization : Keratinocytes at the wound edges and from preserved dermal appendages (hair follicles, sebaceous glands, and eccrine sweat ducts) undergo phenotypic alteration, dissolve hemidesmosomal attachments, and migrate across the provisional matrix (leap-frog and train-movement models) until contact inhibition halts migration.

Phase 4: Remodeling and Maturation Phase (Day 21 to 1–2 Years)

Collagen Isotype Transition : Matrix metalloproteinases (MMPs) systematically degrade loose, fragile Type III collagen , which is replaced by dense, mature Type I collagen organized into thick, parallel bundles oriented along lines of mechanical tension.

Normal Skin Collagen Ratio : Normal unburned dermis has a Type I to Type III collagen ratio of approximately 4:1 (80% Type I, 20% Type III) .

Wound Contraction : A subset of fibroblasts differentiates into myofibroblasts , expressing alpha-smooth muscle actin (α-SMA) within their cytoskeleton. Myofibroblasts anchor to surrounding matrix fibrils and contract, pulling wound edges inward.

Tensile Strength Plateau : Wound tensile strength increases progressively over months:

3 Weeks : ~20% of normal.

6 Weeks : ~50% of normal.

Maximum Plateau (1–2 Years) : 70% to 80% of unwounded skin strength. Burn scar tissue never recovers 100% of the tensile strength or elasticity of native intact skin because elastin fibers fail to regenerate normally.

2. Pathobiology of Abnormal Burn Scarring: Hypertrophic Scars vs. Keloids

Abnormal, fibroproliferative scarring represents one of the most debilitating long-term consequences of thermal injury, resulting in severe physical contractures, chronic pain, neuropathic pruritus, and disfigurement. HYPERTROPHIC SCAR (Common in Burns): KELOID SCAR (Rare in Pure Burns):

  • Extends far beyond original boundary
  • Confined to original burn borders ┌─────────────────────────────────────┐
  • ┌───────────────────────┐ │ │
  • ────────────┘ └───────────┴─ ── ── ── ── ── ── ── ── ── ── ── ──┴────────────
  • Native Skin Elevated, erythematous, Native Skin Tumor-like, claw-like invasion
  • rigid whorls of collagen of adjacent normal dermis

Pathological Feature Hypertrophic Scar (HTS) Keloid Scar

Anatomical Boundary Remains strictly confined within the margins of the original burn wound. Overgrows and invades normal, uninjured surrounding dermis in a pseudotumoral fashion.

Etiology in Burns Very common (>60–70% of deep burns taking >21 days to heal). Rare from thermal injury alone; strongly associated with genetic predisposition and dark-pigmented skin.

Collagen Architecture Organized in nodular, spherical whorls ; high proportion of Type III collagen (ratio Type I:III is ~2:1). Large, disorganized, randomly oriented, glassy, thick, eosinophilic hyalinized collagen bundles .

Myofibroblast Presence Abundant α-SMA-positive myofibroblasts ; active contracture formation. Minimal to absent myofibroblasts; primarily an overproduction of amorphous matrix.

Natural History Tends to undergo slow, partial spontaneous regression over 1–3 years; responds well to pressure garments. Never regresses spontaneously ; continues to enlarge; high recurrence rate (>50–80%) after simple surgical excision.

Location Predilection Flexor surfaces, joints, anterior chest, neck, areas under high mechanical tension. Ear lobes, deltoid, sternum, upper back.

3. The "21-Day Rule" and the Molecular Drivers of Fibrosis

The fundamental clinical guideline governing burn wound surgical management is the 21-Day Rule : Wound Healing Time vs. Hypertrophic Scar Risk:

• Healed in < 14 Days (Superficial partial-thickness): < 10-15% risk of hypertrophic scarring.

• Healed in 14 - 21 Days (Mid partial-thickness): 20 - 35% risk of hypertrophic scarring.

• Healing Requires > 21 Days (Deep partial-thickness): > 70 - 85% risk of severe hypertrophic scarring. ┌─────────────────────────────────────────────────────────────┐

  • │ Prolonged Open Wound & Inflammation (>21 Days) │
  • └──────────────────────────────┬──────────────────────────────┘
  • │
  • ▼
  • ┌─────────────────────────────────────────────────────────────┐
  • │ Sustained Macrophage Activation & Mast Cell Degranulation │
  • │ Massive Overexpression of TGF-β1 and TGF-β2 │
  • └──────────────────────────────┬──────────────────────────────┘
  • │
  • ┌──────────────────────┴──────────────────────┐
  • ▼ ▼
  • ┌──────────────────────────────┐ ┌──────────────────────────────┐
  • │ Myofibroblast Persistence │ │ Extracellular Matrix (ECM) │
  • ├──────────────────────────────┤ ├──────────────────────────────┤
  • │ • Failure of programmed cell │ │ • Uncontrolled Type III │
  • │ death (apoptosis) │ │ collagen deposition │
  • │ • Continuous α-SMA-mediated │ │ • Downregulation of MMPs / │
  • │ mechanical contraction │ │ Upregulation of TIMPs │
  • │ • Joint & skin contractures │ │ • Rigid, inelastic scar mass │
  • └──────────────────────────────┘ └──────────────────────────────┘

Molecular Signaling Mechanisms in Hypertrophic Scarring:

TGF-β Isoform Dysregulation :

TGF-β1 and TGF-β2 : Potent pro-fibrotic cytokines that stimulate fibroblast proliferation, upregulate collagen gene transcription, and induce myofibroblast differentiation.

TGF-β3 : Anti-fibrotic cytokine that promotes scarless fetal-like wound healing. In hypertrophic scars, the ratio of ( T G F − β 1 + T G F − β 2 ) : T G F − β 3 (TGF-\beta1 + TGF-\beta2) : TGF-\beta3 ( TGF − β 1 + TGF − β 2 ) : TGF − β 3 is drastically elevated.

Myofibroblast Apoptosis Resistance : In normal wound healing, myofibroblasts undergo programmed cell death (apoptosis) once the wound is re-epithelialized. In hypertrophic scars, prolonged inflammatory signaling prevents apoptosis, allowing myofibroblasts to perpetually secrete collagen and contract tissue for years.

MMP / TIMP Imbalance : Matrix metalloproteinases (which break down collagen) are suppressed by excessive tissue inhibitors of metalloproteinases ( TIMPs ), leading to net accumulation of rigid, disorganized collagen whorls.

Mast Cell & Histamine-Driven Pruritus : Chronic degranulation of mast cells within the active scar tissue releases histamine, substance P, and serotonin, creating severe, intractable neuropathic and inflammatory burn itch (pruritus) .

4. Clinical Implications for Burn Nursing Practice

Advocacy for Early Excision & Grafting : Wounds identified as deep partial-thickness or full-thickness that will not heal spontaneously within 21 days should undergo early tangential excision and autografting (typically on post-injury days 2–5) to abort the chronic inflammatory cascade and prevent hypertrophic scar formation.

Early Implementation of Compression Therapy : Applying continuous, uniform pressure ( 20 to 30 mmHg ) via custom elastic pressure garments starves the hyperactive scar of microvascular blood supply, induces local tissue hypoxia, accelerates myofibroblast apoptosis, and forces collagen bundles into parallel alignment.

Anti-Deformity Positioning : Because myofibroblasts exert continuous contractile forces, all joints must be positioned in anti-contracture alignment (e.g., neck extension, shoulder abduction at 90°, elbow and knee extension, ankle neutral at 90°) throughout the proliferative and remodeling phases.